Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1831 to 1845 of 9102 results

  1. Point-of-care lipid tests for cardiovascular disease prevention in primary and community care

    Awaiting development Reference number: GID-HTG10528 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  2. Artificial intelligence (AI)-derived software to help clinical decision making in stroke

    Awaiting development Reference number: GID-HTG10529 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  3. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication

    Awaiting development Reference number: GID-HTG10530 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  4. Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]

    Awaiting development Reference number: GID-TA11626 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Epilepsies in children, young people and adults (extraordinary review)

    In development Reference number: GID-NG10378 Expected publication date: TBC

    NICE guideline
    In development

  6. Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care

    Awaiting development Reference number: GID-HTG10531 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  7. Belzutifan for treating advanced pheochromocytoma or paraganglioma [ID6719]

    Awaiting development Reference number: GID-TA11928 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]

    Awaiting development Reference number: GID-TA11917 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

    Technology appraisal Reference number: TA582 Published:  24 May 2019

    Technology appraisal guidance
    In development

  10. Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]

    Awaiting development Reference number: GID-TA10662 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]

    Awaiting development Reference number: GID-TA11325 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Adalimumab for treating early Dupuytren's contracture [ID6276]

    Awaiting development Reference number: GID-TA11363 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Tocilizumab for treating systemic sclerosis [ID1396]

    Awaiting development Reference number: GID-TA10346 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637]

    Awaiting development Reference number: GID-TA11840 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

    In development Reference number: GID-TA10046 Expected publication date:  22 November 2017

    Technology appraisal guidance
    In development